FDA- CLOSELY MONITORING THE RISK OF NEOPLASIA, INCLUDING MALIGNANCY, IN OTHER SIMILAR AAV VECTOR-BASED GENE THERAPY PROGRAMS
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Courtney Rozen WASHINGTON, Nov 6 (Reuters) - The Trump administration canceled a meeting on…
THE REUTERS DAYBOOK CONGRESSIONAL WEEKAHEAD Monday through Friday ----- This is a list of Capitol…
VIDEO SHOWS: HIGHLIGHTS FROM THE QUARTER-FINALS OF THE PARIS MASTERS COMPLETE SHOTLIST AND SCRIPT TO…
Nov 7 (OPTA) - Scores from the PGA Tour-World Wide Technology Championship 2026 World Wide…
By Chibuike Oguh and Marc Jones NEW YORK/LONDON, Nov 6 (Reuters) - Wall Street equities…
Nov 6 (Reuters) - TikTok owner ByteDance is considering expanding a data center project in…